Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular RiskAMG145
Study Details
The primary objective of the study was to evaluate the effect of 12 weeks of subcutaneous evolocumab administered every 2 weeks and once a month, compared with placebo, on percent change from baseline in LDL-C when used in combination with statin therapy in adults with high cardiovascular risk and with hyperlipidemia or mixed dyslipidemia.
Protocol Summary
Mean percent change from baseline in Low Density Lipoprotein Cholesterol (LDL-C)
Timeframe: 10 and 12 Weeks
Percent change from baseline in Low Density Lipoprotein Cholesterol (LDL-C)
Timeframe: 12 Weeks
Mean change from baseline in low density lipoprotein-cholesterol
Timeframe: 10 and 12 Weeks
Change from baseline in low density lipoprotein-cholesterol
Timeframe: 12 Weeks
Mean percent change from baseline in non-high density lipoprotein-cholesterol
Timeframe: 10 and 12 Weeks
Percent change from baseline in non-high density lipoprotein-cholesterol
Timeframe: 12 Weeks
Mean percent change from baseline in apolipoprotein B
Timeframe: 10 and 12 Weeks
Percent change from baseline in apolipoprotein B
Timeframe: 12 Weeks
Mean percent change from baseline in total cholesterol
Timeframe: 10 and 12 Weeks
Percent change from baseline in total cholesterol
Timeframe: 12 Weeks
Mean percent change from baseline in the total cholesterol/high density lipoprotein-cholesterol ratio
Timeframe: 10 and 12 Weeks
Percent change from baseline in the total cholesterol/high density lipoprotein-cholesterol ratio
Timeframe: 12 Weeks
Mean percent change from baseline in apolipoprotein B/apolipoprotein A1 ratio
Timeframe: 10 and 12 Weeks
Percent change from baseline in apolipoprotein B/apolipoprotein A1 ratio
Timeframe: 12 Weeks
Mean low density lipoprotein-cholesterol response (low density lipoprotein-cholesterol < 70 mg/dL [1.8 mmol/L])
Timeframe: 10 and 12 Weeks
Low density lipoprotein-cholesterol response (low density lipoprotein-cholesterol < 70 mg/dL [1.8 mmol/L])
Timeframe: 12 Weeks
Mean percent change from baseline in lipoprotein (a)
Timeframe: 10 and 12 Weeks
Percent change from baseline in lipoprotein (a)
Timeframe: 12 Weeks
Mean percent change from baseline in triglycerides
Timeframe: 10 and 12 Weeks
Percent change from baseline in triglycerides
Timeframe: 12 Weeks
Mean percent change from baseline in high density lipoprotein-cholesterol
Timeframe: 10 and 12 Weeks
Percent change from baseline in high density lipoprotein-cholesterol
Timeframe: 12 Weeks
Mean percent change from baseline in very low-density lipoprotein cholesterol
Timeframe: 10 and 12 Weeks
Percent change from baseline in very low-density lipoprotein cholesterol
Timeframe: 12 Weeks